Opinion
Video
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview
Author(s):
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.
Related Videos
Related Content
